⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7560300 | 0.78 | — | — | |
| SCHEMBL114195 | 0.76 | MGLL (0.58) | — | |
| SCHEMBL145737 | 0.76 | MGLL (0.77) | — | |
| SCHEMBL14678413 | 0.76 | MGLL (0.77) | — | |
| SCHEMBL4619430 | 0.75 | MGLL (0.65) | — | |
| SCHEMBL17629426 | 0.71 | MGLL (0.59) | — | |
| SCHEMBL3726898 | 0.71 | MGLL (0.75) | — | |
| SCHEMBL61934 | 0.71 | MGLL (0.52) | — | |
| SCHEMBL155748 | 0.71 | MGLL (1.00) | — | |
| N-Ethylmaleimide SCHEMBL18209592 | 0.71 | MGLL (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114230654-B | Interleukin-2 capable of covalently crosslinking CD25 and application thereof in autoimmune disease treatment | 中国医学科学院北京协和医院 | 2024-03-08 | — | — | CN | claimed |
| CN-114230654-A | Interleukin-2 capable of covalently crosslinking CD25 and application thereof in treatment of autoimmune diseases | 中国医学科学院北京协和医院 | 2022-03-25 | — | — | CN | claimed |
| CN-115697380-A | PTH analogs for treatment of hypoparathyroidism | 印第安纳大学研究与技术公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-109891237-B | Bioassay of insulin preparations | 诺和诺德股份有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-107108691-B | Method for producing protein | UCB生物制药私人有限公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-112867394-A | anti-VLA-4 antibodies with reduced effector function | 马萨诸塞州渤健公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112543773-A | SIRP alpha-4-1 BBL variant fusion proteins and methods of use thereof | 卡尔医学有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-112543767-A | PD1-4-1BBL variant fusion proteins and methods of use thereof | 卡尔医学有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-10774181-B2 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190330422-A1 | N-MALEIMIDYL POLYMER DERIVATIVES | NEKTAR THERAPEUTICS | 2019-10-31 | — | — | US | disclosed |
| US-10385165-B2 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS (US) | 2019-08-20 | — | — | US | disclosed |
| US-8765111-B2 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130253207-A1 | N-MALEIMIDYL POLYMER DERIVATIVES | NEKTAR THERAPEUTICS (US) | 2013-09-26 | — | — | US | disclosed |
| US-8454946-B2 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS (US) | 2013-06-04 | — | — | US | disclosed |
| US-20060013797-A1 | N-maleimidyl polymer derivatives | NEKTAR THERAPEUTICS | 2006-01-19 | — | — | US | disclosed |
| US-6911197-B2 | Water soluble and non-peptidic polymer backbone having terminal carbon, such as a poly(alkylene glycol), terminal carbon of polymer backbone being directly bonded to nitrogen atom of N-maleimidyl moiety without linking group therebetween | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040109841-A1 | absence of a linker minimizes structural complexity of the derivative and simplifies synthesis of the derivative | NEKTAR THERAPEUTICS AL, CORPORATION | 2004-06-10 | — | — | US | disclosed |
| US-6602498-B2 | Water soluble polymer backbone such as polyethylene glycol, endcapped with a N-maleimidyl moiety without using a linker; conjugated peptides, proteins, nucleotides and drugs | SHEARWATER CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-20010044526-A1 | Water soluble polymer backbone such as polyethylene glycol, endcapped with a N-maleimidyl moiety without using a linker; conjugated peptides, proteins, nucleotides and drugs | SHEARWATER CORPORATION | 2001-11-22 | — | — | US | disclosed |
| WO-2001062827-A2 | N-MALEIMIDYL POLYMER DERIVATIVES | SHEARWATER CORPORATION (US) | 2001-08-30 | — | — | WO | disclosed |